Lower risk of hypoglycemia with insulin detemir than with neutral protamine hagedorn insulin in older persons with type 2 diabetes: A pooled analysis of phase III trials

Journal of the American Geriatrics Society

Volumn 55, Issue 11, 2007, Pages 1735-1740

  Garber, Alan J ^a   Clauson, Per ^b   Pedersen, Claus B ^b   Kølendorf, Klaus ^c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NOVO NORDISK A S   (Denmark)

^c KØGE HOSPITAL   (Denmark)

Author keywords

Aged; Hypoglycemia; Insulin; Type 2 diabetes mellitus

Indexed keywords

HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN ASPART; INSULIN DETEMIR; ISOPHANE INSULIN; ORAL ANTIDIABETIC AGENT;

ADULT; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PHASE 3 CLINICAL TRIAL; POST HOC ANALYSIS; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RISK;

AGED; BLOOD GLUCOSE; CLINICAL TRIALS, PHASE III AS TOPIC; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN, ISOPHANE; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 35748933179     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2007.01414.x     Document Type: Article

References (30)

1. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998 352 : 837 853.
2. Lebovitz HE, Austin MM, Blonde L et al. ACE/AACE Diabetes Recommendations Implementation Writing Committee. ACE/AACE consensus conference on the implementation of outpatient management of diabetes mellitus: Consensus conference recommendations. Endocr Pract 2006 12 (Suppl 1) : 6 12.
3. American Diabetes Association. Clinical practice recommendations. Diabetes Care 2005 28 (Suppl 1) : S1 S3.
4. Resnick HE, Foster GL, Bardsley J et al. Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999-2002: The National Health and Nutrition Examination Survey. Diabetes Care 2006 29 : 531 537.
5. Korzon-Burakowska A, Hopkins D, Matyka K et al. Effects of glycemic control on protective responses against hypoglycemia in type 2 diabetes. Diabetes Care 1998 21 : 283 290.
6. Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care 2003 26 : 1902 1912.
7. Donnelly LA, Morris AD, Frier BM et al. DARTS/MEMO collaboration. Frequency and predictors of hypoglycaemia in Type 1 and insulin-treated Type 2 diabetes: A population-based study. Diabet Med 2005 22 : 749 755.
8. Henderson JN, Allen KV, Deary IJ et al. Hypoglycaemia in insulin-treated Type 2 diabetes: Frequency, symptoms, and impaired awareness. Diabet Med 2003 20 : 1016 1021.
9. Hepburn DA, MacLeod KM, Pell AC et al. Frequency and symptoms of hypoglycaemia experienced by patients with type 2 diabetes treated with insulin. Diabet Med 1993 10 : 231 237.
10. Segel SA, Paramore DS, Cryer PE. Hypoglycemia-associated autonomic failure in advanced type 2 diabetes. Diabetes 2002 51 : 724 733.
11. Cryer PE. Hypoglycaemia: The limiting factor in the glycaemic management of type I and type II diabetes. Diabetologia 2002 45 : 937 948.
12. Holstein A, Plaschke A, Egberts EH. Clinical characterisation of severe hypoglycaemia - a prospective population-based study. Exp Clin Endocrinol Diabetes 2003 111 : 364 369.
13. Matyka K, Evans M, Lomas J et al. Altered hierarchy of protective responses against severe hypoglycemia in normal aging in healthy men. Diabetes Care 1997 20 : 135 141.
14. Hirsch IB. Insulin analogues. N Engl J Med 2005 352 : 174 183.
15. Brunner GA, Sendhofer G, Wutte A et al. Pharmacokinetic and pharmacodynamic properties of long-acting insulin analogue NN304 in comparison to NPH insulin in humans. Exp Clin Endocrinol Diabetes 2000 108 : 100 105.
16. Heinemann L, Sinha K, Weyer C et al. Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304. Diabet Med 1999 16 : 332 338.
17. Haak T, Tiengo A, Draeger E et al. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diab Obes Metab 2005 7 : 56 64.
18. Raslova K, Bogoev M, Raz I et al. Insulin detemir and insulin aspart: A promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract 2004 66 : 193 201. Erratum in: Diab Res Clin Pract 2006;72:112.
19. Hermansen K, Davies M, Derezinski T et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006 29 : 1269 1274.
20. Philis-Tsimikas A, Charpentier G, Clauson P et al. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther 2006 28 : 1569 1581.
21. Wang F, Carabino JM, Vergara CM. Insulin glargine: A systematic review of a long-acting insulin analogue. Clin Ther 2003 25 : 1541 1577.
22. Rosenstock J, Dailey G, Massi-Benedetti M et al. Reduced hypoglycemia risk with insulin glargine: A meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care 2005 28 : 950 955.
23. Bullano MF, Al-Zakwani IS, Fisher MD et al. Differences in hypoglycemia event rates and associated cost-consequence in patients initiated on long-acting and intermediate-acting insulin products. Curr Med Res Opin 2005 21 : 291 298.
24. Eliaschewitz FG, Calvo C, Valbuena H et al. HOE 901/4013 LA Study Group. Therapy in type 2 diabetes: Insulin glargine vs. NPH insulin both in combination with glimepiride. Arch Med Res 2006 37 : 495 501.
25. Home PD, Lindholm A, Riis A. European Insulin Aspart Study Group. Insulin aspart vs. human insulin in the management of long-term blood glucose control in type 1 diabetes mellitus: A randomized controlled trial. Diabet Med 2000 17 : 762 770.
26. Davies M, Derezinski T, Kim H et al. No correlation between weight gain and number of hypoglycemic events in patients with type 2 diabetes treated with insulin detemir as compared to NPH insulin. Diabetes 2006 55 (Suppl 1) : A466.
27. Fritsche A, Haring H. At last, a weight-neutral insulin? Int J Obes 2004 28 (Suppl 2) : S41 S46.
28. Rosenstock J, Schwartz SL, Clark CM Jr. et al. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001 24 : 631 636.
29. Yki-Jarvinen H, Dressler A, Ziemen M. HOE 901/300s Study Group. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care 2000 23 : 1130 1136.
30. Riddle MC, Rosenstock J, Gerich J. Insulin Glargine 4002 Study Investigators. The Treat-to-Target Trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003 26 : 3080 3086.